#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Osteosarcoma recurrent Glomerulonephritis chronic Myasthenia gravis Retinopathy proliferative Dilated cardiomyopathy Angiosarcoma recurrent Mantle cell lymphoma refractory Acute graft versus host disease in intestine Multiple system atrophy Urea cycle disorder Mucous membrane pemphigoid Systemic sclerosis pulmonary Gaucher's disease type III Angiosarcoma Ornithine transcarbamoylase deficiency More trials…

    Learn about Rare Diseases

    Malignant fibrous histiocytoma – Diagnostics Alternating hemiplegia of childhood – Life with Disease Ewing’s sarcoma recurrent – Treatment Fragile X syndrome – Trials in Disease Ewing’s sarcoma – Treatment Small intestine leiomyosarcoma Congenital hypotransferrinaemia – Diagnostics Chronic granulomatous disease – Diagnostics Rhabdomyosarcoma – Life with Disease Idiopathic pulmonary fibrosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    [14C] DC-806 Finerenone Idecabtagene Vicleucel Irinotecan Hydrochloride Amiloride Threonine Etifoxine Hydrochloride Riliprubart Abelacimab Azd8630 SC0062 Rapcabtagene Autoleucel RNMB1 Rocuronium Bromide Ly3454738 SELTOREXANT Guselkumab Cusatuzumab Omeprazole Auto4 More therapies…

    Learn about Your Condition

    Chondropathy Monkeypox Coma Procedural haemorrhage Neurodermatitis Adenocarcinoma gastric Neck pain Thyroid cancer metastatic Vulvovaginal candidiasis Oesophageal adenocarcinoma Lung adenocarcinoma Pulmonary hypertension Neonatal anoxia Becker's muscular dystrophy Bladder cancer More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Tamoxifen
    • Ly3484356
    • Anastrozole
    Austria Belgium Czechia Finland France Germany +10

  • Effect of denosumab versus zoledronic acid on erosion progression in patients with erosive hand osteoarthritis and osteoporosis: a randomized controlled trial

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Osteoporosis
    • Osteoarthritis
    Investigated Drugs:
    • Denosumab
    • Zoledronic Acid Monohydrate
    Italy

  • Effect of Metformin Hydrochloride on Inflammation and Aging Biomarkers in Pre‑diabetic Patients

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Glucose tolerance impaired
    Investigated Drugs:
    • Metformin Hydrochloride
    Spain

  • Advanced hepatocellular carcinoma patients: assessing atezolizumab drug combination and other treatment sequences

    Not yet recruiting

    4 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    Investigated Drugs:
    • Tremelimumab
    • Cabozantinib
    • Sorafenib
    Italy

  • Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

    Not yet recruiting

    2 1
    Investigated Drugs:
    • Crd-4730
    Bulgaria Czechia Hungary Italy Latvia Lithuania +4

  • Phase 3 Study of Romiplostim Combined with Prednisolone versus Prednisolone Alone in Adults with Previously Untreated Primary Immune Thrombocytopenia (ITP)

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Immune thrombocytopenia
    Investigated Drugs:
    • Romiplostim
    • Prednisolone
    Germany Hungary Spain
Previous Page
1 … 662 663 664 665 666 … 1,655
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!